Rein therapeutics announces abstract accepted for presentation at the american thoracic society 2025 international conference

Austin, texas , april 28, 2025 /prnewswire/ -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that an abstract has been accepted at the american thoracic society (ats) 2025 international conference taking place may 18-21, 2025 in san francisco, ca. details of the poster presentation are as follows: presentation title: evaluating alveolar regenerative properties of caveolin scaffolding peptides (csd) in three dimensional (3d) alveolospheres from ipf and normal donor lung samples poster #: p1463 session: b75 targeting cellular senescence, immune dysregulation, and metabolism in lung injury and fibrosis date & time: monday, may 19, 2025, at 11:30 am pt/ 2:30 pm et about rein therapeutics rein therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications.
RNTX Ratings Summary
RNTX Quant Ranking